Effect of early antibiotic treatment on the antibody response to cytoplasmic proteins of Brucella melitensis in mice

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 3, 1999, Pages 440-443

  Bowden, Raul A ^a   Racaro, Graciela C ^b   Baldi, Pablo C ^b  

^a UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; DRUG EFFECT; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032940336     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.3.440-443.1999     Document Type: Article

References (16)

1. Araj, G. F., and A. F. Kaufmann. 1989. Determination by enzyme-linked immunosorbent assay of immunoglobulin G (IgG), IgM, and IgA to Brucella melitensis major outer membrane proteins and whole-cell heat-killed antigens in sera of patients with brucellosis. J. Clin. Microbiol. 27:1909-1912.
2. Ariza, J., J. Corredoira, R. Pallarés, P. F. Viladrich, G. Rufi, M. Pujol, and F. Gudiol. 1995. Characteristics of and risk factors for relapse of brucellosis in humans. Clin. Infect. Dis. 20:1241-1249.
3. Baldi, P. C., S. E. Miguel, C. A. Fossati, and J. C. Wallach. 1996. Serological follow-up of human brucellosis by measuring IgG antibodies directed to S-LPS and cytoplasmic proteins of Brucella. Clin. Infect. Dis. 22:446-455.
4. Baldi, P. C., G. H. Giambartolomei, J. C. Wallach, C. A. Velikovsky, and C. A. Fossati. Different patterns of antibody response to lipopolysaccharide and cytoplasmic proteins of Brucella in human brucellosis of recent onset. Submitted for publication.
5. Cloeckaert, A., H. S. Debbarh, M. S. Zygmunt, and G. Dubray. 1996. Production and characterisation of monoclonal antibodies to Brucella melitensis cytosoluble proteins that are able to differentiate antibody responses of infected sheep from Rev. 1 vaccinated sheep. J. Med. Microbiol. 45:206-213.
6. Debbarh, H. S., M. S. Zygmunt, G. Dubray, and A. Cloeckaert. 1996. Competitive enzyme-linked immunosorbent assay using monoclonal antibodies to the Brucella melitensis BP26 protein to evaluate antibody responses in infected and B. melitensis Rev.1 vaccinated sheep. Vet. Microbiol. 53:325-337.
7. Domingo, S., R. Díaz, and C. Gamazo. 1995. Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice. FEMS Immunol. Med. Microbiol. 12:91-96.
8. Gazapo, E., J. Gonzalez Lahoz, J. L. Subiza, M. Baquero, J. Gil, and E. G. de la Concha. 1989. Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up. J. Infect. Dis. 159:219-225.
9. Goldbaum, F. A., C. P. Rubbi, J. C. Wallach, S. E. Miguel, P. C. Baldi, and C. A. Fossati. 1992. Differentiation between active and inactive human brucellosis by measuring antiprotein humoral immune responses. J. Clin. Microbiol. 30:604-607.
10. Goldbaum, F. A., J. Leoni, J. C. Wallach, and C. A. Fossati. 1993. Characterization of an 18-kilodalton Brucella cytoplasmic protein which appears to be a serological marker of active infection of both human and bovine brucellosis. J. Clin. Microbiol. 31:2141-2145.
11. Jiménez de Bagüés, M. P., P. H. Elzer, J. M. Blasco, C. M. Marín, C. Gamazo, and A. J. Winter. 1994. Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines. Infect. Immun. 62:632-638.
12. Letesson, J.-J., A. Tibor, G. van Eynde, V. Wansard, V. Weynants, P. Denoel, and E. Saman. 1997. Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 4: 556-564.
13. Oliveira, S. C., and G. A. Splitter. 1996. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine 14:959-962.
14. Pellicer, T., J. Ariza, A. Foz, R. Pallares, and F. Gudiol. 1988. Specific antibodies detected during relapse of human brucellosis. J. Infect. Dis. 157: 918-924.
15. Sande, M. A., and G. L. Mandell. 1991. Agentes antimicrobianos: tetraciclinas, cloramfenicol, eritromicina y agentes antibacterianos varios, p. 1083-1109. In A. Goodman Gilman, T. W. Rail, A. S. Nies, and P. Taylor (ed.), Las bases farmacológicas de la terapéutica. Editorial Médica Panamericana, Buenos Aires, Argentina.
16. Serre, A. 1989. Immunology and pathophysiology of human brucellosis, p. 85-95. In E. J. Young and M. J. Corbel (ed.), Brucellosis: clinical and laboratory aspects. CRC Press, Boca Raton, Fla.